TScan Therapeutics (TCRX) Stock Forecast & Price Target

TScan Therapeutics Inc. is poised for a positive outlook due to its promising early efficacy and safety data, particularly with its TCR-T therapy candidates TSC-100 and TSC-101, which demonstrated a significantly lower relapse rate of 8% compared to 33% in the control group, indicating strong potential for clinical success. The company's strategic expansion of its ImmunoBank through additional IND filings, including MAGE-A4 targeting specifically non-small cell lung cancer, will increase patient eligibility for multiplex TCR-T therapies, paving the way for addressing a larger market volume. Furthermore, the commencement of pivotal studies in the second half of 2025 is anticipated to enhance the probability of regulatory approval and long-term value creation from its expanding solid tumor programs.

TScan Therapeutics Inc reported a significant increase in net losses, posting a net loss of $35.8 million, or ($0.30/share) for 4Q24, compared to a net loss of $19.6 million, or ($0.21/share) in 4Q23, indicating deteriorating financial performance. The company's outlook is further constrained by the Bear Case assumptions, which posit that the next clinical update could reveal multiple patient relapses in TSC-100 and TSC-101, potentially leading to a decrease in the probability of success in hematological malignancies to 45%. Lastly, there are concerns regarding TScan's ability to generate successful clinical candidates beyond its initial programs, signaling a lack of diversification in its product pipeline and increased risk for investors.